Search

Search results

399 results found

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.

Kimball, A B, K A Papp, K Reich, M Gooderham, Q Li, N Cichanowitz, C La Rosa, and A Blauvelt. 2020. “Efficacy and Safety of Tildrakizumab for Plaque Psoriasis With Continuous Dosing, Treatment Interruption, Dose Adjustments and Switching from Etanercept: Results from Phase III Studies.”. The British Journal of Dermatology 182 (6): 1359-68.

Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.

Papp, K A, K Reich, A Blauvelt, A B Kimball, M Gooderham, S K Tyring, R Sinclair, et al. 2019. “Efficacy of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Trials at Weeks 12 and 28.”. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (6): 1098-1106.

Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Kimball, A B, M Augustin, K B Gordon, G G Krueger, D Pariser, S Fakharzadeh, K Goyal, et al. 2018. “Correlation of Psoriasis Activity With Socioeconomic Status: Cross-Sectional Analysis of Patients Enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).”. The British Journal of Dermatology 179 (4): 984-86.